Welcome to Scribd. Sign in or start your free trial to enjoy unlimited e-books, audiobooks & documents.Find out more
Download
Standard view
Full view
of .
Look up keyword
Like this
2Activity
0 of .
Results for:
No results containing your search query
P. 1
CBDMT - Market and Business Intelligence - White Biotechnology - The Invisible Revolution

CBDMT - Market and Business Intelligence - White Biotechnology - The Invisible Revolution

Ratings:
(0)
|Views: 69|Likes:
Published by cbdmt
From the first recombinant protein in the 70s, modern biotechnology and more particularly the
industrial or white biotechnology is a real alternative technology for the development and the production of goods from renewable resources (in 2015 up to €300 billion in chemical product sales will be bioproduced). It will allow increasing energy and processing efficiency (cost-effectiveness, flexibility, cleanness, sustainability). So please think not only about pharmaceutical products when we are talking about the 'so trendy' biotechnology market. The invisible white biotechnology revolution is going on.
From the first recombinant protein in the 70s, modern biotechnology and more particularly the
industrial or white biotechnology is a real alternative technology for the development and the production of goods from renewable resources (in 2015 up to €300 billion in chemical product sales will be bioproduced). It will allow increasing energy and processing efficiency (cost-effectiveness, flexibility, cleanness, sustainability). So please think not only about pharmaceutical products when we are talking about the 'so trendy' biotechnology market. The invisible white biotechnology revolution is going on.

More info:

Published by: cbdmt on Apr 22, 2010
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

02/25/2013

pdf

text

original

 
CBDMT Announces The Invisible Revolution: White Biotechnology
From the first recombinant protein in the 70s, modern biotechnology and more particularly theindustrial or white biotechnology is a real alternative technology for the development and the production of goods from renewable resources (in 2015 up to €300 billion in chemical product sales will be bioproduced). It will allow increasing energy and processing efficiency(cost-effectiveness, flexibility, cleanness, sustainability). So please think not only about  pharmaceutical products when we are talking about the 'so trendy' biotechnology market. Theinvisible white biotechnology revolution is going on.
Paris (PRWEB) February 24, 2008 -- The life science market is generally segmented in four segments:Biotechnology, Pharmaceuticals, Diagnostics and Medical Devices. A common problem is the confusion betweenthe biotechnology and pharmaceutical segments. Let us try to clarify a little bit the 'so trendy' biotechnologymarket. In fact, there are two kinds of biotechnology: the traditional and the modern biotechnologies. Thetraditional one is the fermentation mainly used in food and feed applications (Roquette, Danisco, Cargill,ADM…). The modern biotechnology comes from the discovery of recombinant DNA molecules (Stan Cohen andHerb Boyer in 1973), hybridoma technology (Cesar Milstein and Georges Kohler in 1974) and more particularlythe development of molecular biology since then.Let us go from the first biotech company to the invisiblerevolution - the white or industrial biotechnology. The first real modern biotechnology company: Genentech Inc. Genentech Inc. was founded by Herbert Boyer and Robert Swanson in 1976. One year after that, Allan Maxamand Walter Gilbert co-founded Biogen Inc. The same year (1974) Genentech reported the expression of somatostatin, the first human protein produced by a bacterium. In 1980, the first IPO, Genentech went publicOctober 14 at $35/share, raising $35 million. Within one day, the stock leaped to $89/share! The same yearAmgen Inc. was founded. One year later, in 1981 Cal Tech invented an automated gene-sequencing machine thatcan read 7,000 DNA building blocks a day. In 1982, Eli Lilly got the FDA approval to sell the first genetically engineered drug, human insulin cloned byGenentech in 1978. Ten years later, Lilly's Humulin had sales of $702 million. Then, there was the approval of the first biotech industry product, the recombinant human growth hormone (1985), followed by alpha interferonfor cancer treatment and the first genetically engineered vaccine for hepatitis B treatment (1986). In 1994,Calgene received approval to sell its FLAVR SAVER genetically engineered tomato (first GMO food). Today, the global biotechnology market is still young but currently with a value of more than $150 billion and anexpected growth of about 10 to 15% per annum. In 2007, Genentech announced financial results for the full yearwith $11.7 billion total revenue. Genentech is the second most important biotech company behind the leaderAmgen with more than $14.7 billion revenue in 2007. The biotechnology market is more and more commonly segmented by using colors to segment biotechnology
PRWeb eBooks - Anotheronline visibility tool from PRWeb
 
application: -red- for healthcare biotech, -green- for agricultural biotech, -white- for industrial biotech, -blue- formarine biotech, -gold- for bioinformatic- and nanobiotech etc... The original market and certainly the most well-known is the' red biotech' segment which includes medicines anddiagnostics (Top 10 red biotech companies: Amgen, Genentech, Serono, Biogen, Genzyme, Chiron, GileadSciences, CSL, MedImmune, Cephalon). So typically, the red biotech is focused on providing patients withinnovative treatments or diagnostics. This segment includes companies working on cells and tissues, stem cells,gene therapy, orphan drugs, proteomics, pharmacogenetics, genetic testing etc...Red biotechnology: What else? …White biotech for sure. When we use the very fashionable "Bioproduction" word, we generally have in mind pharmaceuticalrecombinant proteins or biopharmaceutical products. This biopharmaceutical market is composed of foursegments: therapeutic proteins extracted from biologics, recombinant therapeutic proteins, cell therapy and genetherapy.This is a huge market estimated to be worth $40 billion in 2004 and expected to be more than $100 billion by2010. As the red biotech or the pharmaceutical biotechnology 'phagocytes' the biotechnology industry, there isimportant information to keep in mind: the white biotechnology or the industrial biotechnology or gene-basedbioindustry also serves other market segments such as detergent, food, feed, cosmetics, R&D etc.The complete article is available onLifeScience Online Philippe Tramoy is Managing Partner at CBDM.T® (CBDMT - Market & Business Intelligence
 
) and can becontacted at contact@cbdmt.com CBDM.T® is a market and business intelligence company with offices in France and in Israel.As an advisory services company, CBDM.T® assists companies to develop revenue and growth by providingbusiness and marketing services in life science and biotech markets (market survey, market scouting, businessdevelopment and strategic supports).See also:CBDMT - Market & Business Inteligence ###
Page 2/3
If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer appears 
here. - PRWeb eBooks - Anotheronline visibility tool from PRWeb

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->